Moreover, METTL3-deficient mice showed attenuated therapeutic efficacy of an anti-PD1 blockade, implying that METTL3 could be a potential target in tumor immunotherapy.219 Tong et al. confirmed that macrophages lacking METTL3 produced less TNF-α. This evidence concerns the gene PDCD1 and neoplasm.